An Efficacy Trial of the Rhesus Rotavirus Vaccine in Maryland
- 1 May 1990
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of Pediatrics & Adolescent Medicine
- Vol. 144 (5), 601-604
- https://doi.org/10.1001/archpedi.1990.02150290095037
Abstract
• A double-blind, placebo-controlled trial of oral rhesus rotavirus vaccine at a dose of 104 plaque-forming units was performed in 114 young infants in Maryland. Significantly more vaccinees than controls had fever and vomiting during the week after vaccination, but these reactions were mild. Of the vaccinees, 83% had a fourfold or greater rise in neutralizing antibody to rhesus rotavirus vaccine and 69% shed vaccine virus. Seventeen percent of the vaccinees and 24% of controls had rotavirus-positive diarrhea during the 2 years of surveillance. Vaccine efficacy was therefore 29% (95% confidence limits, − 31%to + 66%). Stools from 12 of 13 episodes containing sufficient antigen to type were serotype 1. We conclude that rhesus rotavirus vaccine was infective, immunogenic, and probably acceptably attenuated but that this serotype 3 vaccine provided little heterotypic protection during serotype 1 outbreaks in the community. (AJDC. 1990;144:601-604)Keywords
This publication has 5 references indexed in Scilit:
- Systemic and mucosal immune responses to rhesus rotavirus vaccine MMU 18006The Pediatric Infectious Disease Journal, 1988
- PRELIMINARY EVALUATION OF THE EFFICACY OF RHESUS ROTAVIRUS VACCINE STRAIN MMU 18006 IN YOUNG CHILDRENThe Pediatric Infectious Disease Journal, 1986
- Evaluation of Rhesus Rotavirus Vaccine (MMU 18006) in Infants and Young ChildrenThe Journal of Infectious Diseases, 1986
- Serotypic Similarity and Diversity of Rotaviruses of Mammalian and Avian Origin as Studied by Plaque-Reduction NeutralizationThe Journal of Infectious Diseases, 1984
- Chronic rotavirus infection in immunodeficiencyThe Journal of Pediatrics, 1980